Diagnostic, prognostic, and predictive biomarkers in pancreatic cancer

Jordan M. Winter, Charles J. Yeo, Jonathan R. Brody

Research output: Contribution to journalArticlepeer-review

180 Scopus citations


Serum CA 19-9 is the only FDA approved biomarker recommended for use in the routine management of pancreatic ductal adenocarcinoma (PDA). Over 2,000 biomarker studies related to pancreatic cancer appear in the literature, highlighting the need to discover and develop improved tests. Diagnostic biomarkers have implications for early detection of PDA, prognostic markers predict patient survival and recurrence patterns, and predictive markers can help personalize treatment regimens. J. Surg. Oncol. 2013;107:15-22.

Original languageEnglish (US)
Pages (from-to)15-22
Number of pages8
JournalJournal of surgical oncology
Issue number1
StatePublished - Jan 2013
Externally publishedYes


  • biomarkers
  • pancreatic cancer
  • pancreatic ductal adenocarcinoma
  • predictive markers
  • prognostic markers

ASJC Scopus subject areas

  • Surgery
  • Oncology


Dive into the research topics of 'Diagnostic, prognostic, and predictive biomarkers in pancreatic cancer'. Together they form a unique fingerprint.

Cite this